|Trade names||Rompun, Anased, Sedazine, Chanazine|
|AHFS/Drugs.com||International Drug Names|
|oral, inhalation, or injection (intravenous, intramuscular, or subcutaneous)|
|Chemical and physical data|
|3D model (JSmol)|
|(what is this?)|
Xylazine is an analogue of clonidine and an agonist at the α2 class of adrenergic receptor. It is used for sedation, anesthesia, muscle relaxation, and analgesia in animals such as horses, cattle and other non-human mammals. Veterinarians also use xylazine as an emetic, especially in cats.
In veterinary anesthesia, xylazine is often used in combination with ketamine. It is sold under many brand names worldwide, most notably the Bayer brand name Rompun. It is also marketed as Anased, Sedazine, and Chanazine. The drug interactions vary with different animals.
Xylazine is often used as a sedative, muscle relaxant, and analgesic. It is frequently used in the treatment of tetanus. Xylazine is very similar to drugs such as phenothiazine, tricyclic antidepressants, and clonidine. As an anesthetic, it is typically used in conjunction with ketamine. Xylazine appears to reduce sensitivity to insulin and glucose uptake in humans. Yohimbine has been used to decrease glucose levels to a healthy level. In clinical settings, Yohimbine can reverse the adverse effects of xylazine if administered intravenously at a dosage of 0.5 mL / 20 pounds shortly after xylazine administration.
The most common side effects in humans associated with xylazine administration include bradycardia, respiratory depression, hypotension, transient hypertension secondary to vagus nerve stimulation, and other changes in cardiac output. Xylazine significantly decreases heart rate in animals that are not premedicated with medications that have anticholinergic effects. The decrease in heart rate directly impacts aortic flow. Bradycardia caused by xylazine administration is effectively prevented by administration of atropine or glycopyrrolate. Arrhythmias associated with xylazine includes other symptoms such as sinoatrial block, atrioventricular block, A-V dissociation, and sinus arrhythmia.
Xylazine administration can lead to diabetes mellitus and hyperglycemia. Other possible side effects that can occur are areflexia, asthenia, ataxia, blurred vision, disorientation, dizziness, drowsiness, dysarthria, dysmetria, fainting, hyporeflexia, slurred speech, somnolence, staggering, coma, apnea, shallow breathing, sleepiness, premature ventricular contraction, tachycardia, miosis, and dry mouth. Rarely, hypotonia, dry mouth, urinary incontinence and nonspecific electrocardiographic ST segment changes occur. It has been reported that the duration of symptoms after human overdose is 8 to 72 hours. Further research is necessary to categorize the side effects that occur when xylazine is used in conjunction with heroin and cocaine.
Chronic use is reported to be associated with physical deterioration, dependence, abscesses, and skin ulceration, which can be physically debilitating and painful. Hypertension followed by hypotension, bradycardia, and respiratory depression lower tissue oxygenation in the skin. Thus, chronic use of xylazine can progress the skin oxygenation deficit, leading to severe skin ulceration. Lower skin oxygenation is associated with impaired healing of wounds and a higher chance of infection. The ulcers may have a characteristic odor and ooze pus. In severe cases, amputations must be performed on the affected extremities.
The known doses of xylazine that produce toxicity and fatality in humans vary from 40 to 2400 mg. Small doses may produce toxicity and larger doses may be survived with medical assistance. Non-fatal blood or plasma concentration ranges from 0.03 to 4.6 mg/L. In fatalities, the blood concentration of xylazine ranges from trace to 16 mg/L. It is reported that there is no defined safe or fatal concentration of xylazine because of the significant overlap between the non-fatal and postmortem blood concentrations of xylazine.
Currently, there is no specific antidote to treat humans that overdose on xylazine. Hemodialysis has been suggested as a form of treatment, but is usually unfavorable due to the large volume of distribution of xylazine. In addition, due to lack of research in humans, there are no standardized screenings to determine if an overdose has occurred. The detection of xylazine in biological fluids in humans involves various screening methods, such as urine screenings, thin layer chromatography (TLC), gas chromatography mass spectrometry (GC-MS), Remedi HS Bio-Rad Laboratories, and liquid chromatography mass spectrometry (LC-MS).
Multiple drugs have been used as supportive therapeutic intervention such as lidocaine, naloxone, thiamine, lorazepam, vecuronium, etomidate, propofol, tolazoline, yohimbine, atropine, naloxone, orciprenaline, metoclopramide, ranitidine, metoprolol, enoxaparin, flucloxacillin, insulin, and irrigation of both eyes with saline. Effects of xylazine are also reversed by the analeptics 4-aminopyridine, doxapram, and caffeine, which are physiological antagonists to central nervous system depressants. Combining yohimbine and 4-aminopyridine in an effort to antagonize xylazine is superior as compared to the administration of either of these drugs individually due to reduction of recovery time. Research initiatives may be necessary in order to standardize treatment and determine effective measures for identifying chronic xylazine usage and intoxication.
The treatment after xylazine overdose should primarily involve maintaining respiratory function and blood pressure. In cases of intoxication, physicians recommend intravenous fluid infusion, atropine, and hospital observation. Severe cases may require endotracheal intubation, mechanical ventilation, gastric lavage, activated charcoal, bladder catheterization, electrocardiographic (ECG) and hyperglycemia monitoring. Physicians typically recommend which detoxification treatment should be used to manage possible dysfunction involving highly perfused organs, such as the liver and kidney.
Xylazine is a potent α2 adrenergic agonist. When xylazine and other α2 adrenergic receptor agonists are administered, they distribute throughout the body within 30 to 40 minutes. Due to xylazine’s highly lipophilic nature, xylazine directly stimulates central α2 receptors as well as peripheral α-adrenoceptors in a variety of tissues. As an agonist, xylazine leads to a decrease in neurotransmission of norepinephrine and dopamine in the central nervous system. It does so by mimicking norepinephrine in binding to presynaptic surface autoreceptors, which leads to feedback inhibition of norepinephrine.
Xylazine significantly increases Km and does not affect Vmax. Xylazine also serves as a transport inhibitor by suppressing norepinephrine transport function through competitive inhibition of substrate transport. This likely occurs by direct interaction on an area that overlaps with the antidepressant binding site. For example, xylazine and clonidine suppress uptake of MIBG, a norepinephrine analog, in neuroblastoma cells. Xylazine has varying affinities for cholinergic, serotonergic, dopaminergic, α1 adrenergic, H2 - histaminergic and opiate receptors. Its chemical structure closely resembles the phenothiazines, tricyclic antidepressants, and clonidine.
Xylazine is absorbed, metabolized, and eliminated rapidly. Xylazine can be inhaled or administered intravenously, intramuscularly, subcutaneously, or orally either by itself or in conjunction with other anesthetics, such as ketamine, barbiturates, chloral hydrate, and halothane in order to provide reliable anesthesia effects. The most common route of administration is injection. The drug is used as a veterinary anesthetic and the recommended dose varies between species.
Xylazine’s action can be seen usually 15 to 30 minutes after administration and the sedative effect may continue for 1–2 hours and last up to 4 hours. Once xylazine gains access to the vascular system, it is distributed within the blood, allowing xylazine to perfuse target organs including the heart, lungs, liver, and kidney. In nonfatal cases, the blood plasma concentrations range from 0.03 to 4.6 mg/L. Xylazine diffuses extensively and penetrates the blood brain barrier, as expected due to the uncharged, lipophilic nature of the compound.
Xylazine is metabolized by liver cytochrome P450 enzymes. When it reaches the liver, xylazine is metabolized and proceeds to the kidneys to be excreted as urine. Around 70% of a dose is excreted by urine. Thus, urine can be used in detecting xylazine administration because it contains many metabolites, which are the main targets and products in urine. Within a few hours, xylazine decreases to undetectable levels. Other factors can also significantly impact the pharmacokinetics of xylazine, including sex, nutrition, environmental conditions, and prior diseases.
|Xylazine-M (2,6 dimethylaniline)||Xylazine-M (N-thiourea-2,6-dimethylaniline)||Xylazine-M (sulfone-HO-) isomer 2|
|Xylazine-M (HO-2,6-dimethylaniline isomer 1)||Xylazine-M (HO-2,6-dimethylaniline isomer 2)||Xylazine M (oxo-)|
|Xylazine-M (HO-) isomer 1||Xylazine-M (HO-) isomer 1 glucuronide||Xylazine-M (HO-) isomer 2|
|Xylazine-M (HO-) isomer 2 glucuronide||Xylazine-M (HO-oxo-) isomer 1||Xylazine-M (HO-oxo-) isomer 1 glucuronide|
|Xylazine-M (HO-oxo-) isomer 2||Xylazine-M (HO-oxo-) isomer 2 glucuronide||Xylazine-M (sulfone)|
|Xylazine-M (sulfone-HO-) isomer 1|
Xylazine was discovered as an antihypertensive agent in 1962 by Farbenfabriken Bayer in Leverkusen, Germany. Results from early human clinical studies confirmed that xylazine has several central nervous system depressant effects. Xylazine administration is used for sedation, anesthesia, muscle relaxation, and analgesia. It causes a significant reduction in blood pressure and heart rate in healthy volunteers. Due to hazardous side effects, including hypotension and bradycardia, xylazine was not approved by the Food and Drug Administration (FDA) for human use. As a result, xylazine's mechanism of action in humans remains unknown.
Xylazine was approved by the FDA for veterinary use and is now used as an animal tranquilizer. In the United States, xylazine was only approved by the FDA for veterinary use as a sedative, analgesic, and muscle relaxant in dogs, cats, horses, elk, fallow deer, mule deer, sika deer, and white-tailed deer. The sedative and analgesic effects of xylazine are related to central nervous system depression. Xylazine’s muscle relaxant effect inhibits the transmission of neural impulses in the central nervous system.
In scientific research, xylazine is a component of the most common anesthetic, ketamine-xylazine, which is used in rats, mice, hamster, and guinea pigs. The accounts of the actions and uses of xylazine in animals were reported as early as the late 1960s and early 1970s. Since the early 2000s, xylazine has become popular as a drug of abuse in the United States and Puerto Rico. Xylazine’s street name in Puerto Rico is Anestesia de Caballo, which roughly translates to “horse anesthetic." The reasons that may explain why this drug has become increasingly popular are still unknown. Further research is needed to gain more information on the distribution of xylazine in the body, physical symptoms, potential treatments, and predictive factors for chronic usage.
Xylazine users are more likely to be male, under the age of 30, living in a rural area, and injecting versus inhaling xylazine. Xylazine has similar behavioral consequences as heroin, thus it is commonly used as an adulterant. Xylazine is also frequently found in speedball. The combination of heroin and xylazine produces a stronger high than administration of heroin alone. Concomitant use of xylazine with speedball may potentiate or prolong the effects of these drugs, which can lead to adverse consequences.
Carruthers et al. in 1979 reported the first case of xylazine toxicity in a 34-year-old male, who self-medicated for insomnia with injection of 1 g of xylazine. Intentional intoxication from ingesting, inhaling, or injecting xylazine has been reported. The intravenous route is the most common route of administration for those who abuse heroin or xylazine recreationally. In Puerto Rico, xylazine has increased in popularity. Its use was associated with a high number of inmate deaths at the Guerrero Correctional Institution in Aguadilla, Puerto Rico from 2002 through 2008.
In animals, xylazine may be administered intramuscularly or intravenously. As a veterinary anesthetic, xylazine is typically only administered once for intended effect before or during surgical procedures.
Side effects in animals include transient hypertension, hypotension, and respiratory depression. Further, the decrease of tissue sensitivity to insulin leads to xylazine-induced hyperglycemia and a reduction of tissue glucose uptake and utilization. The duration of effects in animals lasts up to 4 hours.
In dogs, sheep, horses and cattle, the half life is very short at only 1.21 to 5.97 minutes. Complete elimination of the half lives can take up to 23.11 minutes in sheep and up to 49.51 minutes in horses. In young rats, the half life is an hour. Xylazine has a large volume of distribution (Vd). The Vd is 1.9-2.5 for horse, cattle, sheep, and dog. Though the peak plasma concentrations are reached in 12–14 minutes in all species, the bioavailability varies between species. The half life depends on the age of the animal, as age is related to prolonged duration of anesthesia and recovery time. Toxicity occurs with repeated administration, given that the metabolic clearance of the drug is usually calculated as 7 to 9 times the half-life, which is 4 to 5 days for the clearance of xylazine.
- Greene, SA; Thurmon, JC (December 1988). "Xylazine--a review of its pharmacology and use in veterinary medicine". Journal of Veterinary Pharmacology and Therapeutics. 11 (4): 295–313. doi:10.1111/j.1365-2885.1988.tb00189.x. PMID 3062194.
- Xylazine at drugs.com
- by Patricia M. Dowling & Johann (Hans) Coetzee for the Merck Manual. Last full review/revision March 2012 Drugs to Control or Stimulate Vomiting Archived April 7, 2015, at the Wayback Machine. (Monogastric)
- Ruiz-Colón, K; Chavez-Arias, C; Díaz-Alcalá, JE; Martínez, MA (July 2014). "Xylazine intoxication in humans and its importance as an emerging adulterant in abused drugs: A comprehensive review of the literature". Forensic Science International. 240: 1–8. doi:10.1016/j.forsciint.2014.03.015. PMID 24769343.
- Haskins, SC; Patz, JD; Farver, TB (March 1986). "Xylazine and xylazine-ketamine in dogs". American Journal of Veterinary Research. 47 (3): 636–41. PMID 3963565.
- Muir, WW; Skarda, RT; Milne, DW (February 1977). "Evaluation of xylazine and ketamine hydrochloride for anesthesia in horses". American Journal of Veterinary Research. 38 (2): 195–201. PMID 842917.
- Aithal, HP; Pratap, AK; Singh, GR (1997). "Clinical effects of epidurally administered ketamine and xylazine in goats". Small Ruminant Research. 24 (1): 55–64. doi:10.1016/s0921-4488(96)00919-4.
- Torruella, RA (11 April 2011). "Xylazine (veterinary sedative) use in Puerto Rico". Substance Abuse Treatment, Prevention, and Policy. 6: 7. doi:10.1186/1747-597x-6-7. PMC . PMID 21481268.
- Reyes, JC; Negrón, JL; Colón, HM; Padilla, AM; Millán, MY; Matos, TD; Robles, RR (June 2012). "The emerging of xylazine as a new drug of abuse and its health consequences among drug users in Puerto Rico". Journal of Urban Health. 89 (3): 519–26. doi:10.1007/s11524-011-9662-6. PMC . PMID 22391983.
- Xiao, YF; Wang, B; Wang, X; Du, F; Benzinou, M; Wang, YX (20 October 2013). "Xylazine-induced reduction of tissue sensitivity to insulin leads to acute hyperglycemia in diabetic and normoglycemic monkeys". BMC Anesthesiology. 13 (1): 33. doi:10.1186/1471-2253-13-33. PMC . PMID 24138083.
- Silva-Torres, L; Veléz, C; Alvarez, L; Zayas, B (2014). "Xylazine as a drug of abuse and its effects on the generation of reactive species and DNA damage on human umbilical vein endothelial cells". Journal of Toxicology. 2014: 492609. doi:10.1155/2014/492609. PMC . PMID 25435874.
- Meyer, GM; Maurer, HH (December 2013). "Qualitative metabolism assessment and toxicological detection of xylazine, a veterinary tranquilizer and drug of abuse, in rat and human urine using GC-MS, LC-MSn, and LC-HR-MSn". Analytical and Bioanalytical Chemistry. 405 (30): 9779–89. doi:10.1007/s00216-013-7419-7. PMID 24141317.
- Ndeereh, DR; Mbithi, PM; Kihurani, DO (June 2001). "The reversal of xylazine hydrochloride by yohimbine and 4-aminopyridine in goats". Journal of the South African Veterinary Association. 72 (2): 64–7. doi:10.4102/jsava.v72i2.618. PMID 11513261.
- Elliott; et al. (30 September 1986). "Process for the Production of Xylazine". United States Patent.
- Delehant, TM; Denhart, JW; Lloyd, WE; Powell, JD (2003). "Pharmacokinetics of xylazine, 2,6-dimethylaniline, and tolazoline in tissues from yearling cattle and milk from mature dairy cows after sedation with xylazine hydrochloride and reversal with tolazoline hydrochloride". Veterinary Therapeutics. 4 (2): 128–34. PMID 14506588.
- Park, JW; Chung, HW; Lee, EJ; Jung, KH; Paik, JY; Lee, KH (29 April 2013). "α2-Adrenergic agonists including xylazine and dexmedetomidine inhibit norepinephrine transporter function in SK-N-SH cells". Neuroscience Letters. 541: 184–9. doi:10.1016/j.neulet.2013.02.022. PMID 23485735.
- Veilleux-Lemieux, D; Castel, A; Carrier, D; Beaudry, F; Vachon, P (September 2013). "Pharmacokinetics of ketamine and xylazine in young and old Sprague-Dawley rats". Journal of the American Association for Laboratory Animal Science. 52 (5): 567–70. PMC . PMID 24041212.
- Barroso, M; Gallardo, E; Margalho, C; Devesa, N; Pimentel, J; Vieira, DN (April 2007). "Solid-phase extraction and gas chromatographic- mass spectrometric determination of the veterinary drug xylazine in human blood". Journal of Analytical Toxicology. 31 (3): 165–9. doi:10.1093/jat/31.3.165. PMID 17579964.
- McCurnin, DM, and JM Bassert. Clinical Textbook for Veterinary Technicians, 5th ed. Saunders, Philadelphia, PA. 2002.
- Bayer Healthcare - Rompun Homepage https://web.archive.org/web/20070302155131/http://www.rompun.com:80/ 2005.
- Wright, Bob. Human health concerns when working with medications around horses. Agdex# 460. Ontario Ministry of Agriculture, Food and Rural Affairs (OMAFRA). 2000.